Literature DB >> 25082150

The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.

Juliana C Small1, Larissa H Haut2, Ang Bian2, Hildegund C J Ertl3.   

Abstract

In this study, we tested the effect of neutralizing Abs to different serotypes of E1-deleted Ad vectors on the immunogenicity of the homologous Ad vector or a vector derived from a heterologous serotype. Our results showed that, as expected, even low titers of passively transferred neutralizing Abs significantly reduced the homologous vectors' ability to elicit transgene-specific CD8(+) T cell responses. In addition, Abs changed the fate of transgene product-specific CD8(+) T cells by promoting their transition into the central memory cell pool, which resulted in markedly enhanced expansion of transgene product-specific CD8(+) T cells after a boost with a heterologous Ad vector. Non-neutralizing Abs specific to a distinct Ad serotype had no effect on the magnitude of transgene product-specific CD8(+) T cells induced by a heterologous Ad vector, nor did such Abs promote induction of more resting memory CD8(+) T cells. These results show that Abs to an Ad vaccine carrier affect not only the magnitude but also the profile of a vector-induced CD8(+) T cell response.
© 2014 Society for Leukocyte Biology.

Entities:  

Keywords:  AdHu5 immune serum; HIV vaccine; STEP trial; adenovirus hexon; virus neutralizing antibodies

Mesh:

Substances:

Year:  2014        PMID: 25082150      PMCID: PMC4197559          DOI: 10.1189/jlb.1A0813-451RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  29 in total

1.  Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

Authors:  H Chen; Z Q Xiang; Y Li; R K Kurupati; B Jia; A Bian; D M Zhou; N Hutnick; S Yuan; C Gray; J Serwanga; B Auma; P Kaleebu; X Zhou; M R Betts; H C J Ertl
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.

Authors:  Dongming Zhou; Xiangyang Zhou; Ang Bian; Hua Li; Heng Chen; Juliana C Small; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Nat Protoc       Date:  2010-10-14       Impact factor: 13.491

3.  Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag.

Authors:  Larissa H Haut; Shih W Lin; Nia Tatsis; Lauren J DiMenna; Wynetta Giles-Davis; Aguinaldo R Pinto; Hildegund C J Ertl
Journal:  Eur J Immunol       Date:  2010-11-11       Impact factor: 5.532

4.  Early signals during CD8 T cell priming regulate the generation of central memory cells.

Authors:  Joshua J Obar; Leo Lefrançois
Journal:  J Immunol       Date:  2010-06-02       Impact factor: 5.422

Review 5.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

6.  Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Authors:  Clayton D Harro; Michael N Robertson; Michelle A Lally; Lori D O'Neill; Srilatha Edupuganti; Paul A Goepfert; Mark J Mulligan; Frances H Priddy; Sheri A Dubey; Lisa S Kierstead; Xiao Sun; Danilo R Casimiro; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Devan V Mehrotra
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

7.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

8.  Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.

Authors:  Adel Benlahrech; Julian Harris; Andrea Meiser; Timos Papagatsias; Julia Hornig; Peter Hayes; Andre Lieber; Takis Athanasopoulos; Veronique Bachy; Eszter Csomor; Rod Daniels; Kerry Fisher; Frances Gotch; Len Seymour; Karen Logan; Romina Barbagallo; Linda Klavinskis; George Dickson; Steven Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

9.  Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.

Authors:  Scott G Hansen; Julia C Ford; Matthew S Lewis; Abigail B Ventura; Colette M Hughes; Lia Coyne-Johnson; Nathan Whizin; Kelli Oswald; Rebecca Shoemaker; Tonya Swanson; Alfred W Legasse; Maria J Chiuchiolo; Christopher L Parks; Michael K Axthelm; Jay A Nelson; Michael A Jarvis; Michael Piatak; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2011-05-11       Impact factor: 49.962

10.  Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.

Authors:  Matthieu Perreau; Giuseppe Pantaleo; Eric J Kremer
Journal:  J Exp Med       Date:  2008-11-03       Impact factor: 14.307

View more
  5 in total

1.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

2.  Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.

Authors:  Qianqian Li; Qiang Liu; Weijing Huang; Aijing Song; Chenyan Zhao; Jiajing Wu; Youchun Wang
Journal:  Hum Vaccin Immunother       Date:  2017-03-16       Impact factor: 3.452

3.  Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.

Authors:  Hua Zhao; Can Xu; Xiaoli Luo; Feng Wei; Ning Wang; Huiying Shi; Xiubao Ren
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

Review 4.  HLA-E: exploiting pathogen-host interactions for vaccine development.

Authors:  H R Sharpe; G Bowyer; S Brackenridge; T Lambe
Journal:  Clin Exp Immunol       Date:  2019-04-09       Impact factor: 4.330

5.  Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.

Authors:  Adam E Snook; Trevor R Baybutt; Bo Xiang; Tara S Abraham; John C Flickinger; Terry Hyslop; Tingting Zhan; Walter K Kraft; Takami Sato; Scott A Waldman
Journal:  J Immunother Cancer       Date:  2019-04-23       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.